A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

540

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary IgA Nephropathy

Interventions

DRUG: LNP023

Sponsor

Novartis Pharmaceuticals